Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
This study has been completed.
Study NCT00305903 Information provided by Novartis
First Received: March 20, 2006 Last Updated: December 17, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Alzheimer's Disease
Additional conditions recognized in this trial
Alzheimer Disease
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Dementia
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies
Interventions listed in this trial
Rivastigmine, memantine
Additional drug interventions recognized in this trial
Memantine
Rivastigmine
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Cholinergic Agents
Cholinesterase Inhibitors
Dopamine Agents
Enzyme Inhibitors
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Novartis
Back to top of Main Content
